50
Participants
Start Date
December 9, 2020
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Everolimus
Given PO
Trametinib
Given PO
RECRUITING
New York University, New York
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
Children's National Medical Center, Washington D.C.
RECRUITING
John Hopkins University, Baltimore
RECRUITING
University of Alabama at Birmingham, Children's of Alabama, Birmingham
RECRUITING
Riley Hospital for Children, Indianapolis
RECRUITING
Children's Minnesota, Minneapolis
RECRUITING
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RECRUITING
Washington University in St. Louis, St Louis
RECRUITING
University Of Texas Southwestern Medical Center, Dallas
RECRUITING
Texas Children's Hospital, Houston
RECRUITING
Children's Hospital Los Angeles, Los Angeles
RECRUITING
University of California, San Diego Rady Children's Hospital, San Diego
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Doernbecher Children's Hospital Oregon Health & Science University, Portland
RECRUITING
University of Florida, Gainesville
WITHDRAWN
Dana Farber Cancer Institute, Boston
RECRUITING
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Pediatric Brain Tumor Foundation
UNKNOWN
The Lilabean Foundation for Pediatric Brain Cancer Research
UNKNOWN
University of California, San Francisco
OTHER